ClinicalTrials.gg
CompletedNCT01005901GLOW 1Updated Apr 12, 2012Results posted

A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo

A Phase 3 interventional study of Glycopyrronium bromide and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Novartis. Completed at 97 sites in 11 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2012-04-12.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,324
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
9th of 73
1,324 · median 152
Started
2009
with 3 others
Phase 3
33 of 73
1 open now
Registered
9th of 73
by date
Lead sponsor
6 of 73
Novartis

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 9th largest by enrollment, is one of 4 that started in 2009, is one of 33 in phase 3, and was the 9th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

A study to assess the safety, tolerability and efficacy of NVA237 versus placebo in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • COPD
  • NVA
  • FEV1
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2008) and:
  • Smoking history of at least 10 pack-years
  • Post-bronchodilator \< 80% and ≥ 30% of the predicted normal value
  • Post-bronchodilator FEV1/FVC (forced vital capacity) \< 70%

Exclusion criteria

Exclusion Criteria:

  1. Patients who have had a lower respiratory tract infection within 6 weeks prior to Visit 1
  2. Patients with concomitant pulmonary disease
  3. Patients with a history of asthma
  4. Any patient with lung cancer or a history of lung cancer
  5. Patients with a history of certain cardiovascular comorbid conditions
  6. Patients with a known history and diagnosis of alpha-1 antitrypsin deficiency
  7. Patients in the active phase of a supervised pulmonary rehabilitation program
  8. Patients for tiotropium or ipratropium treatment or who have shown an untoward reaction to inhaled anticholinergic agents Other protocol-defined inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,324 participants (actual)

Study arms

  • Experimental
    Glycopyrronium bromide

    Glycopyrronium bromide 50µg delivered once daily via Single Dose Dry Powder Inhaler (SDDPI). At visit 1 all patients were provided with a short acting β2-agonist (salbutamol/albuterol) which they were instructed to use throughout the study as rescue medication.

    Drug: Glycopyrronium bromide

  • Placebo comparator
    Placebo

    Placebo delivered once daily via SDDPI. At Visit 1 all patients were provided with a short acting β2-agonist (salbutamol/albuterol) which they were instructed to use throughout the study as rescue medication.

    Drug: Placebo

Interventions

  • Glycopyrronium bromide 50µg was supplied as inhalation capsules for use via a Single Dose Dry Powder Inhaler (SDDPI)

  • DrugPlacebo

    Placebo inhalation capsules were provided for use via a SDDPI

06

What researchers measure

Primary outcomes

  1. Trough Forced Expiratory Volume in 1 Second (FEV1) at 12 Weeks

    Spirometry was conducted according to internationally accepted standards. Trough FEV1 was defined as the average of the 23 hour 15 minute and 23 hour 45 minute post-dose FEV1 readings. Mixed model used baseline FEV1,baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.

    Time frame: 12 weeks

Secondary outcomes

  1. Transition Dyspnea Index (TDI) Focal Score After 26 Weeks of Treatment

    Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline. Mixed model used baseline TDI, baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.

    Time frame: 26 weeks

  2. Quality of Life Assessment With St. George's Respiratory Questionnaire (SGRQ) Total Score After 26 Weeks of Treatment

    SGRQ is a health related quality of life questionnaire consisting of 51 items in three components: symptoms, activity, and impacts. The lowest possible value is zero and the highest 100. Higher values correspond to greater impairment in quality of life. Mixed model used baseline SGRQ, baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.

    Time frame: 26 weeks

  3. Time to First Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation During 26 Weeks of Treatment

    The time to the first moderate or severe COPD exacerbation was the study day on which the patient experienced first moderate or severe COPD exacerbation. COPD exacerbations are considered to be moderate if treatment with systemic corticosteroids and/or antibiotics was required. COPD exacerbations are considered to be severe if treatment for moderate severity and hospitalization were required.

    Time frame: 26 weeks

  4. Change From Baseline in the Mean Number of Puffs Per Day of Rescue Medication Over the Study Duration (Baseline to Week 26)

    Participants recorded the number of puffs of rescue medication taken in the previous 12 hours in the morning and evening. The total number of puffs of rescue medication per day over the full 26 weeks was calculated and divided by the total number of days with non-missing rescue medication data to derive the mean daily number of puffs of rescue medication taken for the patient.

    Time frame: 26 weeks

  5. FEV1 at Each Time-point on Day 1 and Week 26

    Spirometry was conducted according to internationally accepted standards. FEV1 was measured at all time points up to 4 hours post-dose, and at 23 hours 15 min and 23 hours 45 min, by visit. Mixed model used baseline FEV1,baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.

    Time frame: Day 1 and Week 26

  6. Forced Vital Capacity (FVC) at Each Time-point on Day 1 and Week 26

    Spirometry was conducted according to internationally accepted standards. FVC was calculated at each time point up to 4 hours post-dose and at 23 hours 15 min and 23 hours 45 min, by visit. Mixed model used baseline FVC, baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.

    Time frame: Day 1 and Week 26

  7. FEV1 Area Under the Curve (AUC) (5 Min - 12 Hour) at Day 1, Week 12 and Week 26

    The standardized (with respect to the length of time) area under the curve (AUC) for FEV1 was calculated using trapezoidal rule between 5 min and 12 h post dose at Week 1 Day 1, Week 12 and Week 26 for every patient in the serial spirometry subgroup. Mixed model used baseline FEV1,baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.

    Time frame: Day 1, Week 12 and Week 26

  8. FEV1 Area Under Curve (AUC) (5 Min - 23 Hour 45 Min) at Week 12 and Week 26

    The standardized (with respect to the length of time) area under the curve (AUC) for FEV1 was calculated using trapezoidal rule between 5 min and 23 h 45 min post dose at week12/week 13and week 26/week 27 where available for every patient in the serial spirometry subgroup. Mixed model used baseline FEV1,baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.

    Time frame: Week 12 and Week 26

  9. Trough FEV1 and FVC at Day 1 and Week 26

    Spirometry was conducted according to internationally accepted standards. Trough FEV1 was defined as the average of the 23 hour 15 minute and 23 hour 45 minute post-dose FEV1 readings. Mixed model used baseline FEV1, baseline ICS use, FEV1 prior to inhalation of SABA, and FEV1 45 minutes post-inhalation of SABA as covariates. Trough FVC was defined as the average of the 23 hour 15 minute and 23 hour 45 minute post-dose FVC readings. Mixed model used baseline FVC, baseline ICS use, FEV1 prior to inhalation of SABA, and FEV1 45 minutes post-inhalation of SABA as covariates.

    Time frame: Day 1 and Week 26

  10. Change in 24-hourly Mean Heart Rate at Day 1, Week 12 and Week 26

    The mean heart rate was collected with a 24 hour Holter monitor in a sub-set of the safety population. The change between baseline and day 1, week 12 and week 26 was calculated. The analysis of the Holter recordings was performed by a central facility. Data on heart rate, heart rate variability, supraventricular and ventricular ectopy were collected and assessed.

    Time frame: Baseline, Day 1, Week 12 and Week 26

  11. Number of Participants With Adverse Events, Death, and Serious or Clinically Significant Adverse Events or Related Discontinuations

    Adverse events are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.

    Time frame: 26 Weeks and 30 Day follow-up

  12. Rate of Moderate or Severe COPD Exacerbations Over the 26 Week Treatment Period

    One overall rate is calculated for the entire study population. Rate is the number of moderate or severe exacerbations per year = total number of moderate or severe exacerbations for all participants/total number of treatment years for all participants. COPD exacerbations were considered to be moderate if treatment with systemic corticosteroids and/or antibiotics was required. COPD exacerbations were considered to be severe if treatment for moderate severity and hospitalization were required.

    Time frame: 26 weeks

  13. Percentage of Nights With no Nighttime Awakenings Over the 26 Week Treatment Period

    The percentage of nights with no nighttime awakenings is defined as the total number of nights with no nighttime awakenings over the 26 week treatment period divided by the total number of night where diary recordings have been made. Mixed model used baseline nighttime awakenings, baseline ICS use, FEV1 prior to inhalation of SABA, and FEV1 45 minutes post-inhalation of SABA as covariates.

    Time frame: 26 Weeks

  14. Percentage of Days With no Daytime Symptoms Over the 26 Week Treatment Period

    The percentage of days with no daytime symptoms is defined as the total number of days with no daytime symptoms over the 26 week treatment period divided by the total number of days where diary recordings have been made. Mixed model used baseline daytime symptoms, baseline ICS use, FEV1 prior to inhalation of SABA, and FEV1 45 minutes post-inhalation of SABA as covariates.

    Time frame: 26 Weeks

  15. Percentage of Days Able to Perform Usual Daily Activities Over the 26 Week Treatment Period

    The percentage of days able to perform usual daily activities is defined as the total number of days able to perform usual activities over the 26 week treatment period divided by the total number of days where diary recordings have been made. Mixed model used baseline ability to perform usual daily activities, baseline ICS use, FEV1 prior to inhalation of SABA, and FEV1 45 minutes post-inhalation of SABA as covariates.

    Time frame: 26 Weeks

  16. Mean Daily Total Symptom Score Over the 26 Week Treatment Period

    The daily symptom score was calculated as the sum of the worst of the morning and evening assessments for each symptom (symptoms, cough, wheeze, sputum color/production, and breathlessness). The score can range from 0 to 18 with 0 indicating no symptoms. The higher the score, the worse the symptomatic status. A negative change (lower number) indicates improvement. Mixed model used baseline symptom variables, baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.

    Time frame: 26 Weeks

07

Results

Posted Apr 12, 2012

Participant flow

Participant flow — Overall Study
MilestoneGlycopyrronium BromidePlacebo
Started552270
Safety population550267
Full analysis set534260
Completed450212
Not completed10258
Withdrew: Withdrawal by subject3814
Withdrew: Adverse event3016
Withdrew: Administrative problems2113
Withdrew: Unsatisfactory therapeutic effect55
Withdrew: Protocol violation43
Withdrew: Death23
Withdrew: Lost to follow-up12
Withdrew: Patient's inability to use the device11
Withdrew: No longer requires study drug01

Outcome measures

PrimaryTrough Forced Expiratory Volume in 1 Second (FEV1) at 12 Weeks

Spirometry was conducted according to internationally accepted standards. Trough FEV1 was defined as the average of the 23 hour 15 minute and 23 hour 45 minute post-dose FEV1 readings. Mixed model used baseline FEV1,baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.

Time frame:
12 weeks
Reported as:
Least squares mean · Liters
Trough Forced Expiratory Volume in 1 Second (FEV1) at 12 Weeks
LitersGlycopyrronium BromidePlacebo
Trough Forced Expiratory Volume in 1 Second (FEV1) at 12 Weeks1.408 ± 0.01051.301 ± 0.0137
SecondaryTransition Dyspnea Index (TDI) Focal Score After 26 Weeks of Treatment

Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline. Mixed model used baseline TDI, baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.

Time frame:
26 weeks
Reported as:
Least squares mean · Units on a scale
Transition Dyspnea Index (TDI) Focal Score After 26 Weeks of Treatment
Units on a scaleGlycopyrronium BromidePlacebo
Transition Dyspnea Index (TDI) Focal Score After 26 Weeks of Treatment1.84 ± 0.2570.80 ± 0.294
SecondaryQuality of Life Assessment With St. George's Respiratory Questionnaire (SGRQ) Total Score After 26 Weeks of Treatment

SGRQ is a health related quality of life questionnaire consisting of 51 items in three components: symptoms, activity, and impacts. The lowest possible value is zero and the highest 100. Higher values correspond to greater impairment in quality of life. Mixed model used baseline SGRQ, baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.

Time frame:
26 weeks
Reported as:
Least squares mean · Units on a scale
Quality of Life Assessment With St. George's Respiratory Questionnaire (SGRQ) Total Score After 26 Weeks of Treatment
Units on a scaleGlycopyrronium BromidePlacebo
Quality of Life Assessment With St. George's Respiratory Questionnaire (SGRQ) Total Score After 26 Weeks of Treatment39.50 ± 0.81342.31 ± 0.992
SecondaryTime to First Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation During 26 Weeks of Treatment

The time to the first moderate or severe COPD exacerbation was the study day on which the patient experienced first moderate or severe COPD exacerbation. COPD exacerbations are considered to be moderate if treatment with systemic corticosteroids and/or antibiotics was required. COPD exacerbations are considered to be severe if treatment for moderate severity and hospitalization were required.

Time frame:
26 weeks
Reported as:
Median · Days
Time to First Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation During 26 Weeks of Treatment
DaysGlycopyrronium BromidePlacebo
Time to First Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation During 26 Weeks of TreatmentNA (NA to NA)NA (NA to NA)
SecondaryChange From Baseline in the Mean Number of Puffs Per Day of Rescue Medication Over the Study Duration (Baseline to Week 26)

Participants recorded the number of puffs of rescue medication taken in the previous 12 hours in the morning and evening. The total number of puffs of rescue medication per day over the full 26 weeks was calculated and divided by the total number of days with non-missing rescue medication data to derive the mean daily number of puffs of rescue medication taken for the patient.

Time frame:
26 weeks
Reported as:
Least squares mean · Puffs per day
Change From Baseline in the Mean Number of Puffs Per Day of Rescue Medication Over the Study Duration (Baseline to Week 26)
Puffs per dayGlycopyrronium BromidePlacebo
Change From Baseline in the Mean Number of Puffs Per Day of Rescue Medication Over the Study Duration (Baseline to Week 26)-1.21 ± 0.122-0.75 ± 0.156
SecondaryFEV1 at Each Time-point on Day 1 and Week 26

Spirometry was conducted according to internationally accepted standards. FEV1 was measured at all time points up to 4 hours post-dose, and at 23 hours 15 min and 23 hours 45 min, by visit. Mixed model used baseline FEV1,baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.

Time frame:
Day 1 and Week 26
Reported as:
Least squares mean · Liters
FEV1 at Each Time-point on Day 1 and Week 26
LitersGlycopyrronium BromidePlacebo
Day 1: 5 min (n = 497, 240)1.388 ± 0.00571.295 ± 0.0076
Day 1: 15 min (n = 503, 249)1.435 ± 0.00661.292 ± 0.0087
Day 1: 30 min (n = 511, 252)1.472 ± 0.00701.299 ± 0.0093
Day 1: 1 hour (n = 513, 253)1.493 ± 0.00701.296 ± 0.0094
Day 1: 2 hours (n = 514, 251)1.562 ± 0.00761.355 ± 0.0102
Day 1: 3 hours (n = 519, 248)1.544 ± 0.00791.349 ± 0.0108
Day 1: 4 hours (n = 514, 247)1.548 ± 0.00771.365 ± 0.0105
Day 1: 23 hours 15 min (n = 499, 244)1.400 ± 0.00781.289 ± 0.0103
Day 1: 23 hours 45 min (n = 498, 244)1.428 ± 0.00831.328 ± 0.0108
Week 26: pre-dose trough (n = 447, 208)1.371 ± 0.01001.256 ± 0.0140
Week 26: -45 min (n = 447, 208)1.373 ± 0.01041.256 ± 0.0145
Week 26: -15 min (n = 443, 205)1.368 ± 0.01041.252 ± 0.0144
Week 26: 5 min (n = 439, 208)1.409 ± 0.01061.255 ± 0.0147
Week 26: 15 min (n = 435, 205)1.427 ± 0.01091.269 ± 0.0152
Week 26: 30 min (n = 440, 207)1.433 ± 0.01121.259 ± 0.0155
Week 26: 1 hour (n = 438, 206)1.459 ± 0.01151.251 ± 0.0159
Week 26: 2 hours (n = 438, 203)1.508 ± 0.01141.299 ± 0.0160
Week 26: 3 hours (n = 439, 204)1.504 ± 0.01241.299 ± 0.0170
Week 26: 4 hours (n = 438, 205)1.489 ± 0.01141.312 ± 0.0158
Week 26: 23 hours 15 min (n = 434, 206)1.386 ± 0.01181.267 ± 0.0158
Week 26: 23 hours 45 min (n = 434, 206)1.396 ± 0.01161.282 ± 0.0157
SecondaryForced Vital Capacity (FVC) at Each Time-point on Day 1 and Week 26

Spirometry was conducted according to internationally accepted standards. FVC was calculated at each time point up to 4 hours post-dose and at 23 hours 15 min and 23 hours 45 min, by visit. Mixed model used baseline FVC, baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.

Time frame:
Day 1 and Week 26
Reported as:
Least squares mean · Liters
Forced Vital Capacity (FVC) at Each Time-point on Day 1 and Week 26
LitersGlycopyrronium BromidePlacebo
Day 1: 5 min (n = 497, 240)2.887 ± 0.01322.675 ± 0.0173
Day 1: 15 min (n = 503, 249)2.943 ± 0.01472.660 ± 0.0188
Day 1: 30 min (n = 511, 252)2.948 ± 0.01552.637 ± 0.0199
Day 1: 1hour (n = 513, 253)3.019 ± 0.01482.669 ± 0.0198
Day 1: 2 hours (n = 514, 251)3.086 ± 0.01662.754 ± 0.0219
Day 1: 3 hours (n = 519, 248)3.096 ± 0.01682.783 ± 0.0227
Day 1: 4 hours (n = 514, 247)3.064 ± 0.01612.760 ± 0.0217
Day 1: 23 hours 15 min (n = 499, 244)2.895 ± 0.01692.693 ± 0.0221
Day 1: 23 hours 45 min (n = 498, 244)2.907 ± 0.01692.718 ± 0.0219
Week 26: Pre-dose trough (n = 447, 208)2.827 ± 0.02382.623 ± 0.0305
Week 26: -45 min (n = 447, 208)2.859 ± 0.02712.658 ± 0.0337
Week 26: -15 min (n = 443, 205)2.798 ± 0.02352.589 ± 0.0306
Week 26: 5 min (n = 439, 208)2.891 ± 0.02512.639 ± 0.0318
Week 26: 15 min (n = 435, 205)2.895 ± 0.02402.660 ± 0.0309
Week 26: 30 min (n = 440, 207)2.885 ± 0.02392.603 ± 0.0310
Week 26: 1 hour (n = 438, 206)2.938 ± 0.02562.625 ± 0.0329
Week 26: 2 hours (n = 438, 203)2.977 ± 0.02252.687 ± 0.0302
Week 26: 3 hours (n = 439, 204)3.016 ± 0.02702.742 ± 0.0345
Week 26: 4 hours (n = 438, 205)2.962 ± 0.02252.709 ± 0.0303
Week 26: 23 hours 15 min (n = 434, 206)2.884 ± 0.02572.673 ± 0.0322
Week 26: 23 hours 45 min (n = 434, 206)2.859 ± 0.02342.669 ± 0.0306
SecondaryFEV1 Area Under the Curve (AUC) (5 Min - 12 Hour) at Day 1, Week 12 and Week 26

The standardized (with respect to the length of time) area under the curve (AUC) for FEV1 was calculated using trapezoidal rule between 5 min and 12 h post dose at Week 1 Day 1, Week 12 and Week 26 for every patient in the serial spirometry subgroup. Mixed model used baseline FEV1,baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.

Time frame:
Day 1, Week 12 and Week 26
Reported as:
Least squares mean · Liters
FEV1 Area Under the Curve (AUC) (5 Min - 12 Hour) at Day 1, Week 12 and Week 26
LitersGlycopyrronium BromidePlacebo
Day 1 (n = 169, 83)1.475 ± 0.01291.320 ± 0.0173
Week 12 (n = 153, 75)1.433 ± 0.01791.284 ± 0.0244
Week 26 (n = 149, 70)1.445 ± 0.01991.238 ± 0.0274
SecondaryFEV1 Area Under Curve (AUC) (5 Min - 23 Hour 45 Min) at Week 12 and Week 26

The standardized (with respect to the length of time) area under the curve (AUC) for FEV1 was calculated using trapezoidal rule between 5 min and 23 h 45 min post dose at week12/week 13and week 26/week 27 where available for every patient in the serial spirometry subgroup. Mixed model used baseline FEV1,baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.

Time frame:
Week 12 and Week 26
Reported as:
Least squares mean · Liters
FEV1 Area Under Curve (AUC) (5 Min - 23 Hour 45 Min) at Week 12 and Week 26
LitersGlycopyrronium BromidePlacebo
Week 12 (n = 153, 75)1.401 ± 0.01671.268 ± 0.0228
Week 26 (n = 149, 70)1.412 ± 0.01851.213 ± 0.0254
SecondaryTrough FEV1 and FVC at Day 1 and Week 26

Spirometry was conducted according to internationally accepted standards. Trough FEV1 was defined as the average of the 23 hour 15 minute and 23 hour 45 minute post-dose FEV1 readings. Mixed model used baseline FEV1, baseline ICS use, FEV1 prior to inhalation of SABA, and FEV1 45 minutes post-inhalation of SABA as covariates. Trough FVC was defined as the average of the 23 hour 15 minute and 23 hour 45 minute post-dose FVC readings. Mixed model used baseline FVC, baseline ICS use, FEV1 prior to inhalation of SABA, and FEV1 45 minutes post-inhalation of SABA as covariates.

Time frame:
Day 1 and Week 26
Reported as:
Least squares mean · Liters
Trough FEV1 and FVC at Day 1 and Week 26
LitersGlycopyrronium BromidePlacebo
Day 1: FEV1 (n = 508, 248)1.414 ± 0.00751.309 ± 0.0099
Week 26: FEV1 (n = 461, 217)1.387 ± 0.01121.275 ± 0.0150
Day 1: FVC (n = 508, 248)2.901 ± 0.01542.705 ± 0.0202
Week 26: FVC (n = 438, 208)2.867 ± 0.02362.668 ± 0.0300
SecondaryChange in 24-hourly Mean Heart Rate at Day 1, Week 12 and Week 26

The mean heart rate was collected with a 24 hour Holter monitor in a sub-set of the safety population. The change between baseline and day 1, week 12 and week 26 was calculated. The analysis of the Holter recordings was performed by a central facility. Data on heart rate, heart rate variability, supraventricular and ventricular ectopy were collected and assessed.

Time frame:
Baseline, Day 1, Week 12 and Week 26
Reported as:
Mean · beats per minute
Change in 24-hourly Mean Heart Rate at Day 1, Week 12 and Week 26
beats per minuteGlycopyrronium BromidePlacebo
Day 1: (n = 42, 23)-1.77 ± 7.583-1.28 ± 8.676
Week 12: (n = 42, 20)-1.99 ± 7.489-1.70 ± 7.230
Week 26: (n = 37, 22)-4.40 ± 9.347-2.60 ± 9.349
SecondaryNumber of Participants With Adverse Events, Death, and Serious or Clinically Significant Adverse Events or Related Discontinuations

Adverse events are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.

Time frame:
26 Weeks and 30 Day follow-up
Reported as:
Number · participants
Number of Participants With Adverse Events, Death, and Serious or Clinically Significant Adverse Events or Related Discontinuations
participantsGlycopyrronium BromidePlacebo
Participants with at least one AE317174
Death33
SAE(s)4124
Discontinuation due to AE(s)3219
Discontinuation due to SAE(s)158
Discontinuation due to non-SAE(s)1811
AE leading to dose interruption128
AE requiring significant additional therapy246155
AE leading to new or prolonged hospitalization3521
SecondaryRate of Moderate or Severe COPD Exacerbations Over the 26 Week Treatment Period

One overall rate is calculated for the entire study population. Rate is the number of moderate or severe exacerbations per year = total number of moderate or severe exacerbations for all participants/total number of treatment years for all participants. COPD exacerbations were considered to be moderate if treatment with systemic corticosteroids and/or antibiotics was required. COPD exacerbations were considered to be severe if treatment for moderate severity and hospitalization were required.

Time frame:
26 weeks
Reported as:
Number · exacerbations per year
Rate of Moderate or Severe COPD Exacerbations Over the 26 Week Treatment Period
exacerbations per yearGlycopyrronium BromidePlacebo
Rate of Moderate or Severe COPD Exacerbations Over the 26 Week Treatment Period0.430.59
SecondaryPercentage of Nights With no Nighttime Awakenings Over the 26 Week Treatment Period

The percentage of nights with no nighttime awakenings is defined as the total number of nights with no nighttime awakenings over the 26 week treatment period divided by the total number of night where diary recordings have been made. Mixed model used baseline nighttime awakenings, baseline ICS use, FEV1 prior to inhalation of SABA, and FEV1 45 minutes post-inhalation of SABA as covariates.

Time frame:
26 Weeks
Reported as:
Least squares mean · percentage of nights with no awakenings
Percentage of Nights With no Nighttime Awakenings Over the 26 Week Treatment Period
percentage of nights with no awakeningsGlycopyrronium BromidePlacebo
Percentage of Nights With no Nighttime Awakenings Over the 26 Week Treatment Period55.96 ± 1.53754.37 ± 1.970
SecondaryPercentage of Days With no Daytime Symptoms Over the 26 Week Treatment Period

The percentage of days with no daytime symptoms is defined as the total number of days with no daytime symptoms over the 26 week treatment period divided by the total number of days where diary recordings have been made. Mixed model used baseline daytime symptoms, baseline ICS use, FEV1 prior to inhalation of SABA, and FEV1 45 minutes post-inhalation of SABA as covariates.

Time frame:
26 Weeks
Reported as:
Least squares mean · percentage of days with no symptoms
Percentage of Days With no Daytime Symptoms Over the 26 Week Treatment Period
percentage of days with no symptomsGlycopyrronium BromidePlacebo
Percentage of Days With no Daytime Symptoms Over the 26 Week Treatment Period5.70 ± 0.7995.78 ± 1.076
SecondaryPercentage of Days Able to Perform Usual Daily Activities Over the 26 Week Treatment Period

The percentage of days able to perform usual daily activities is defined as the total number of days able to perform usual activities over the 26 week treatment period divided by the total number of days where diary recordings have been made. Mixed model used baseline ability to perform usual daily activities, baseline ICS use, FEV1 prior to inhalation of SABA, and FEV1 45 minutes post-inhalation of SABA as covariates.

Time frame:
26 Weeks
Reported as:
Least squares mean · percentage of days
Percentage of Days Able to Perform Usual Daily Activities Over the 26 Week Treatment Period
percentage of daysGlycopyrronium BromidePlacebo
Percentage of Days Able to Perform Usual Daily Activities Over the 26 Week Treatment Period40.31 ± 1.47335.19 ± 1.907
SecondaryMean Daily Total Symptom Score Over the 26 Week Treatment Period

The daily symptom score was calculated as the sum of the worst of the morning and evening assessments for each symptom (symptoms, cough, wheeze, sputum color/production, and breathlessness). The score can range from 0 to 18 with 0 indicating no symptoms. The higher the score, the worse the symptomatic status. A negative change (lower number) indicates improvement. Mixed model used baseline symptom variables, baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.

Time frame:
26 Weeks
Reported as:
Least squares mean · units on a scale
Mean Daily Total Symptom Score Over the 26 Week Treatment Period
units on a scaleGlycopyrronium BromidePlacebo
Mean Daily Total Symptom Score Over the 26 Week Treatment Period-1.54 ± 0.097-1.18 ± 0.129

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Glycopyrronium Bromide—41/550 (7.5%)132/550 (24%)
Placebo—24/267 (9%)85/267 (31.8%)
Most frequent serious events
Showing 10 of 61
Most frequent serious events
EventGlycopyrronium BromidePlacebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders9/55011/267
Myocardial ischaemiaCardiac disorders0/5502/267
PneumoniaInfections and infestations4/5502/267
Upper respiratory tract infectionInfections and infestations0/5502/267
Upper respiratory tract infection bacterialInfections and infestations3/5502/267
Atrial fibrillationCardiac disorders3/5500/267
AnaemiaBlood and lymphatic system disorders0/5501/267
Cardiac arrestCardiac disorders0/5501/267
Myocardial infarctionCardiac disorders2/5501/267
Abdominal painGastrointestinal disorders0/5501/267
Most frequent other events
Most frequent other events
EventGlycopyrronium BromidePlacebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders105/55067/267
NasopharyngitisInfections and infestations28/55021/267
Upper respiratory tract infectionInfections and infestations23/55020/267

Baseline characteristics

Age, Customized
Age, Customized(participants)Glycopyrronium BromidePlaceboTotal
<65 years278134412
65 to <75 years19998297
>=75 years7335108
Sex: Female, Male
Sex: Female, Male(Participants)Glycopyrronium BromidePlaceboTotal
Female9652148
Male454215669
08

Study locations

97 sites
  • Novartis Investigative Site
    Birmingham, Alabama, United States
  • Novartis Investigative Site
    Fairhope, Alabama, United States
  • Novartis Investigative Site
    Glendale, Arizona, United States
  • Novartis Investigative Site
    Los Angeles, California, United States
  • Novartis Investigative Site
    Walnut Creek, California, United States
  • Novartis Investigative Site
    Newark, Delaware, United States
  • Novartis Investigative Site
    Port Orange, Florida, United States
  • Novartis Investigative Site
    Tamarac, Florida, United States
  • Novartis Investigative Site
    Topeka, Kansas, United States
  • Novartis Investigative Site
    Madisonville, Kentucky, United States
  • Novartis Investigative Site
    Slidell, Louisiana, United States
  • Novartis Investigative Site
    Biddeford, Maine, United States
  • Novartis Investigative Site
    Pikesville, Maryland, United States
  • Novartis Investigative Site
    Ann Arbor, Michigan, United States
  • Novartis Investigative Site
    Livonia, Michigan, United States
  • Novartis Investigative Site
    Minneapolis, Minnesota, United States
  • Novartis Investigative Site
    Kansas City, Missouri, United States
  • Novartis Investigative Site
    St. Charles, Missouri, United States
  • Novartis Investigative Site
    Missoula, Montana, United States
  • Novartis Investigative Site
    Bellevue, Nebraska, United States
  • Novartis Investigative Site
    Omaha, Nebraska, United States
  • Novartis Investigative Site
    Reno, Nevada, United States
  • Novartis Investigative Site
    New Brunswick, New Jersey, United States
  • Novartis Investigative Site
    Rochester, New York, United States
  • Novartis Investigative Site
    Cincinnati, Ohio, United States
  • Novartis Investigative Site
    Oklahoma City, Oklahoma, United States
  • Novartis Investigative Site
    Tulsa, Oklahoma, United States
  • Novartis Investigative Site
    Lincoln, Rhode Island, United States
  • Novartis Investigative Site
    Johnson City, Tennessee, United States
  • Novartis Investigative Site
    Corpus Christi, Texas, United States
  • Novartis Investigative Site
    McKinney, Texas, United States
  • Novartis Investigative Site
    San Antonio, Texas, United States
  • Novartis Investigative Site
    Richmond, Virginia, United States
  • Novartis Investigative Site
    Daw Park SA, Australia
  • Novartis Investigative Site
    Bridgewater, Nova Scotia, Canada
  • Novartis Investigative Site
    Courtice, Ontario, Canada
  • Novartis Investigative Site
    Mississuaga, Ontario, Canada
  • Novartis Investigative Site
    North York, Ontario, Canada
  • Novartis Investigative Site
    Ottawa, Ontario, Canada
  • Novartis Investigative Site
    Toronto, Ontario, Canada
  • Novartis Investigative Site
    Montreal, Quebec, Canada
  • Novartis Investigative Site
    Asahikawa, Japan
  • Novartis Investigative Site
    Hamakita, Japan
  • Novartis Investigative Site
    Himeji, Japan
  • Novartis Investigative Site
    Hitachi, Japan
  • Novartis Investigative Site
    Kishiwada, Japan
  • Novartis Investigative Site
    Kyoto, Japan
  • Novartis Investigative Site
    Matsue, Japan
  • Novartis Investigative Site
    Matsusaka, Japan
  • Novartis Investigative Site
    Moriya, Japan
  • Novartis Investigative Site
    Naka-gun, Japan
  • Novartis Investigative Site
    Obihiro, Japan
  • Novartis Investigative Site
    Osaka, Japan
  • Novartis Investigative Site
    Ota, Japan
  • Novartis Investigative Site
    Otsu, Japan
  • Novartis Investigative Site
    Sapporo, Japan
  • Novartis Investigative Site
    Takatsuki, Japan
  • Novartis Investigative Site
    Tokyo, Japan
  • Novartis Investigative Site
    Yabu, Japan
  • Novartis Investigative Site
    Yonezawa, Japan
  • Novartis Investigative Site
    Daegu, Korea, Republic of
  • Novartis Investigative Site
    Pusan, Korea, Republic of
  • Novartis Investigative site
    Seoul, Korea, Republic of
  • Novartis Investigative Site
    Almelo, Netherlands
  • Novartis Investigative Site
    Eindhoven, Netherlands
  • Novartis Investigative Site
    Harderwijk, Netherlands
  • Novartis Investigative Site
    Heerlen, Netherlands
  • Novartis Investigative Site
    Zutphen, Netherlands
  • Novartis Investigative Site
    Bucharest, Romania
  • Novartis Investigative Site
    Bucuresti, Romania
  • Novartis Investigative Site
    Iasi, Romania
  • Novartis Investigative Site
    Timisoara, Romania
  • Novartis Investigative Site
    Irkutsk, Russian Federation
  • Novartis Investigative Site
    Kazan, Russian Federation
  • Novartis Investigative Site
    Krasnodar, Russian Federation
  • Novartis Investigative Site
    Moscow, Russian Federation
  • Novartis Investigative Site
    N. Novgorod, Russian Federation
  • Novartis Investigative Site
    Novosibirsk, Russian Federation
  • Novartis Investigative Site
    Sochy, Russian Federation
  • Novartis Investigative Site
    Stavropol, Russian Federation
  • Novartis Investigative Site
    Yaroslavl, Russian Federation
  • Novartis Investigative Site
    Singapore, Singapore
  • Novartis Investigative Site
    Alicante, Spain
  • Novartis Investigative Site
    Badalona, Spain
  • Novartis Investigative Site
    Caceres, Spain
  • Novartis Investigative Site
    Canet de Mar, Spain
  • Novartis Investigative Site
    Centelles, Spain
  • Novartis Investigative Site
    Valencia, Spain
  • Novartis Investigative Site
    Altunizade, Turkey
  • Novartis Investigative Site
    Aydin, Turkey
  • Novartis Investigative Site
    Diyarbakir, Turkey
  • Novartis Investigative Site
    Istanbul, Turkey
  • Novartis Investigative Site
    Izmir, Turkey
  • Novartis Investigative Site
    Kinikli/Denizli, Turkey
  • Novartis Investigative Site
    Mersin, Turkey
  • Novartis Investigative Site
    Soke/Aydin, Turkey
  • Novartis Investigative Site
    Yenisehir/Izmir, Turkey
09

References and documents

Publications

  • D'Urzo A, Ferguson GT, van Noord JA, Hirata K, Martin C, Horton R, Lu Y, Banerji D, Overend T. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011 Dec 7;12(1):156. doi: 10.1186/1465-9921-12-156. PubMed 22151296 ↗
  • D'Urzo A, Kerwin E, Overend T, D'Andrea P, Chen H, Goyal P. Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies. Curr Med Res Opin. 2014 Mar;30(3):493-508. doi: 10.1185/03007995.2013.858618. Epub 2013 Nov 19. PubMed 24156566 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2012, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2009
First posted
Nov 1, 2009
Start
Oct 2009
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Results first posted
Apr 12, 2012
Last update
Apr 12, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01005901
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Nov 1, 2009
Start date
Oct 2009
Primary completion
Dec 2010
Completion
Dec 2010
Results posted
Apr 12, 2012
Last update
Apr 12, 2012

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion